Payment overview · 2025
General Payments
$21,836.12
93 reported records · 18 companies
Healthcare provider profile · identity verified
David Stephen Wang, MD
Allopathic & Osteopathic Physicians|Radiology|Vascular & Interventional Radiology · STANFORD, CA · NPI 1932396116
Verified facts
What the public records show
CMS Open Payments records show David Stephen Wang, MD received $21,836.12 in general payments during 2025 across 93 reported records.
W. L. Gore & Associates, Inc. accounted for 48.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $10,592.71 | 48.5% | 9 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $3,645.25 | 16.7% | 26 | 2025 |
| HISTOSONICS, INC. | Unresolved — no canonical attribution shown | $2,204.28 | 10.1% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $1,934.34 | 8.9% | 7 | 2025 |
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $1,162.07 | 5.3% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $447.95 | 2.0% | 7 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $424.67 | 1.9% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $347.26 | 1.6% | 18 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $227.14 | 1.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$200.91 | 0.9% | 2 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $159.90 | 0.7% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $146.42 | 0.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $134.27 | 0.6% | 1 | 2025 |
| Galvanize Therapeutics, Inc | Unresolved — no canonical attribution shown | $72.43 | 0.3% | 1 | 2025 |
| TriSalus Life Sciences, Inc. | Unresolved — no canonical attribution shown | $67.11 | 0.3% | 1 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $27.29 | 0.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $23.62 | 0.1% | 1 | 2025 |
| Okami Medical, Inc. | Unresolved — no canonical attribution shown | $18.50 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $8,625.00 | 2 |
| Travel and Lodging | $7,538.28 | 21 |
| Food and Beverage | $5,672.84 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $8,647.91 | 3 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $2,561.64 | 8 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $1,934.34 | 7 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $1,810.61 | 4 | 2025 |
Source payment records
|
|||||
| LAVA LES (Liquid Embolic System) Normalized: lava les liquid embolic system |
Device | Sirtex Medical Inc | $1,117.25 | 8 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $227.14 | 1 | 2025 |
Source payment records
|
|||||
| EMPRINT Normalized: emprint |
Device | Medtronic, Inc. | $200.91 | 2 | 2025 |
Source payment records
|
|||||
| Stingray Normalized: stingray |
Device | Boston Scientific Corporation | $169.97 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $159.90 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $159.90 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $149.24 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $146.42 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $144.96 | 1 | 2025 |
Source payment records
|
|||||
| General - Embolics Normalized: general embolics |
Device | Boston Scientific Corporation | $140.36 | 1 | 2025 |
Source payment records
|
|||||
| EMBOLD Fibered Normalized: embold fibered |
Device | Boston Scientific Corporation | $139.09 | 3 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $138.88 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $134.19 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $133.90 | 9 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $129.28 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $100.34 | 3 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $74.86 | 2 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $74.38 | 1 | 2025 |
Source payment records
|
|||||
| ALIYA SYSTEM Normalized: aliya system |
Device | Galvanize Therapeutics, Inc | $72.43 | 1 | 2025 |
Source payment records
|
|||||
| TRINAV INFUSION SYSTEM Normalized: trinav infusion system |
Device | TriSalus Life Sciences, Inc. | $67.11 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $60.28 | 3 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $59.02 | 1 | 2025 |
Source payment records
|
|||||
| TheraSphere Administration Set Normalized: therasphere administration set |
Device | Boston Scientific Corporation | $54.87 | 1 | 2025 |
Source payment records
|
|||||
| SIR-Spheres Microspheres Normalized: sir spheres microspheres |
Device | Sirtex Medical Inc | $44.82 | 2 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $37.22 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $29.80 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| LOBO Normalized: lobo |
Device | Okami Medical, Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| OBSIDIO Normalized: obsidio |
Device | Boston Scientific Corporation | $16.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,836.12 · 93 records | W. L. Gore & Associates, Inc. | ALIYA SYSTEM, AMPLATZER AMULET, AVVIGO Guidance System, AngioJet Ultra 5000A, Asahi Peripheral Vascular Wires, COROFLOW, CT THROMBECTOMY SYSTEM KIT, DRAGONFLY OPSTAR, EMBOLD Fibered, EMPRINT, EVOQUE, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GORE VIABAHN Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, General - Balloon Catheters, General - Embolics, General - Vascular Intervention, Indigo System, LAVA LES (Liquid Embolic System), LOBO, MITRACLIP, OBSIDIO, Product in Development, ROTAPRO, SAPIEN 3 Ultra RESILIA, SIR-Spheres Microspheres, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Stingray, TRINAV INFUSION SYSTEM, TheraSphere Administration Set, TheraSphere Y90 Glass Microspheres 10 GBq, ULTREON, Venovo, WATCHMAN, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error